Lymphatic Diseases 
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lymphatic Diseases
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Active, not recruiting
2
140
Europe
cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2
Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories
Primary Central Nervous System Lymphoma
05/16
05/26
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
1
70
US, Europe
GDC-0199 (ABT-199), Obinutuzumab
Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd
Lymphocytic Leukemia, Chronic
01/15
11/16
NCT01999491: A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

Active, not recruiting
1
39
US
NC-4016
M.D. Anderson Cancer Center, NanoCarrier Co., Ltd.
Advanced Cancers, Lymphoma
11/18
11/18
EMTP, NCT00590915: Erwinase Master Treatment Protocol

No Longer Available
N/A
US
Erwinia L-asparaginase, Erwinase
Phoenix Children's Hospital, Fisher Bioservices, Jazz Pharmaceuticals
Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia
 
 
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

No Longer Available
N/A
US
Plerixafor, AMD3100, Mozobil
Genzyme, a Sanofi Company
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
 
 
EAP, NCT02197650: Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase

No Longer Available
N/A
Europe
suspension of erythrocytes encapsulating L-asparaginase, GRASPA®, eryaspase
ERYtech Pharma
Acute Lymphoblastic Leukemia
 
 

Download Options